Published in Eur J Cancer Clin Oncol on February 01, 1983
Who should measure quality of life, the doctor or the patient? Br J Cancer (1988) 6.32
Are quality of life measures patient centred? BMJ (2001) 2.59
Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer (2004) 2.41
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer (1997) 1.88
The impact of nausea and vomiting upon quality of life measures. Br J Cancer Suppl (1992) 1.81
What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease. Br J Cancer (1996) 1.37
Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes (2003) 1.34
Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care. Br J Cancer (1997) 1.19
The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer (2004) 1.19
Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag (2007) 1.19
Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer (2004) 1.16
Stability of an extemporaneous oral liquid aprepitant formulation. Support Care Cancer (2008) 1.13
Understanding and improving platinum anticancer drugs--phenanthriplatin. Anticancer Res (2014) 1.10
Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer (2008) 1.05
Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits (2012) 1.05
Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists. Int J Clin Oncol (2009) 1.05
Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ (1993) 1.03
Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer (2010) 1.01
Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer (1997) 1.00
Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. Support Care Cancer (2008) 0.99
Symptom assessment in children receiving cancer therapy: the parents' perspective. Support Care Cancer (2009) 0.97
A review of patient self-report tools for chemotherapy-induced nausea and vomiting. Support Care Cancer (2008) 0.97
Efficacy of Rasayana Avaleha as adjuvant to radiotherapy and chemotherapy in reducing adverse effects. Ayu (2010) 0.97
Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells. ACS Nano (2014) 0.97
Acceptance of oral chemotherapy in breast cancer patients - a survey study. BMC Cancer (2011) 0.96
Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. Br Med J (Clin Res Ed) (1986) 0.94
Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer (2010) 0.94
Preparing patients for threatening medical treatments: effects of a chemotherapy educational DVD on anxiety, unmet needs, and self-efficacy. Support Care Cancer (2007) 0.93
A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist (2011) 0.91
Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. Br J Cancer (1990) 0.90
Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer (2007) 0.89
Treatment decisions in advanced ovarian cancer. Br J Cancer (1989) 0.89
Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413. Br J Cancer (1997) 0.88
Comparison of starting antiemetic treatment 24 hours before or concurrently with cytotoxic chemotherapy. BMJ (1989) 0.87
A qualitative study investigating chemotherapy-induced nausea as a symptom cluster. Support Care Cancer (2014) 0.87
A systematic review of symptom assessment scales in children with cancer. BMC Cancer (2012) 0.87
A qualitative exploration of Malaysian cancer patients' perspectives on cancer and its treatment. BMC Public Health (2011) 0.87
The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group. Br J Cancer (1993) 0.86
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care Cancer (2015) 0.86
A quantitative approach to the distress caused by symptoms in patients treated with radical radiotherapy. Br J Cancer (1996) 0.85
Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. Br J Cancer (2003) 0.83
Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer (1998) 0.83
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer (2016) 0.83
Distress associated with radiotherapy for malignant disease: a quantitative analysis based on patients perceptions. Br J Cancer (1989) 0.82
Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol (2012) 0.81
Anticipatory nausea and emesis, and psychological morbidity: assessment of prevalence among out-patients on mild to moderate chemotherapy regimens. Br J Cancer (1992) 0.81
An overview of the clinical use of ondansetron in preschool age children. Ther Clin Risk Manag (2007) 0.80
Role of Biomarkers in the Development of PARP Inhibitors. Biomark Cancer (2016) 0.80
Minimising treatment-associated risks in systemic cancer therapy. Pharm World Sci (2007) 0.80
Chemotherapy-induced complications in patients with lung cancer: An evaluation by pharmacists. Mol Clin Oncol (2012) 0.80
Predictors of response to palliative care intervention for chronic nausea in advanced cancer outpatients. Support Care Cancer (2013) 0.79
Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther (2017) 0.79
Initial development of the Symptom Screening in Pediatrics Tool (SSPedi). Support Care Cancer (2013) 0.79
Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients. Cancer Res Treat (2004) 0.79
Defining novel health-related quality of life domains in lung transplantation: a qualitative analysis. Qual Life Res (2014) 0.79
Nausea and vomiting and cancer patients' quality of life: a discussion of Professor Selby's paper. Br J Cancer Suppl (1992) 0.79
Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. Support Care Cancer (2004) 0.78
Polydopamine Nanoparticles as a Versatile Molecular Loading Platform to Enable Imaging-guided Cancer Combination Therapy. Theranostics (2016) 0.78
The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew. Pharmacol Biochem Behav (2008) 0.78
Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group. Br J Cancer (1994) 0.78
Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag (2009) 0.78
A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of therasnostic agents. Nat Commun (2015) 0.78
5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis. Br J Cancer (1996) 0.78
Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. Surg Endosc (2013) 0.78
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. Support Care Cancer (2013) 0.78
Supportive cryotherapy: a review from head to toe. J Pain Symptom Manage (2013) 0.77
Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. Support Care Cancer (2005) 0.77
Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Arch Dis Child (1995) 0.77
Refinement of the symptom screening in pediatrics tool (SSPedi). Br J Cancer (2014) 0.77
Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. Support Care Cancer (2016) 0.76
Antiemetic effects of granisetron and dexamethasone combination therapy during cisplatin-containing chemotherapy for head and neck cancer: dexamethasone dosage verification trial. Int J Clin Oncol (2009) 0.75
[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research]. Med Klin (Munich) (1998) 0.75
Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron. Cancer Manag Res (2009) 0.75
Crystal structures of organoplatinum complexes containing alkyl-eugenoxyacetate and p-chloro-aniline. Acta Crystallogr E Crystallogr Commun (2016) 0.75
Dual-pH Sensitive Charge-reversal Nanocomplex for Tumor-targeted Drug Delivery with Enhanced Anticancer Activity. Theranostics (2017) 0.75
Anti-emetic effect of high-dose metoclopramide vs alizapride--a randomised crossover study. Br J Clin Pharmacol (1994) 0.75
The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial. Br J Cancer (1989) 0.75
Examining the effects of adjuvant chemotherapy on cognition and the impact of any cognitive impairment on quality of life in colorectal cancer patients: study protocol. BMC Psychol (2015) 0.75
Recent Advances on Inorganic Nanoparticle-Based Cancer Therapeutic Agents. Int J Environ Res Public Health (2016) 0.75
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. Br J Cancer (1996) 0.75
Patient preferences for side effects associated with cervical cancer treatment. Int J Gynecol Cancer (2014) 0.75
Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines? J Transl Int Med (2016) 0.75
Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology. Cancer Med (2016) 0.75
In vitro biomechanical properties, fluorescence imaging, surface-enhanced Raman spectroscopy, and photothermal therapy evaluation of luminescent functionalized CaMoO4:Eu@Au hybrid nanorods on human lung adenocarcinoma epithelial cells. Sci Technol Adv Mater (2016) 0.75
Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens. Br Med J (Clin Res Ed) (1987) 0.75
Controlled release tablet formulation containing natural Δ(9)-tetrahydrocannabinol. Drug Dev Ind Pharm (2015) 0.75
Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Support Care Cancer (2016) 0.75
Text Messaging (SMS) Helping Cancer Care in Patients Undergoing Chemotherapy Treatment: a Pilot Study. J Med Syst (2017) 0.75
Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms. Support Care Cancer (2016) 0.75
Patient perceptions of symptoms and concerns during cancer chemotherapy: 'affects my family' is the most important. Int J Clin Oncol (2017) 0.75
Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Int J Clin Oncol (2016) 0.75
Mn(2+)-coordinated PDA@DOX/PLGA nanoparticles as a smart theranostic agent for synergistic chemo-photothermal tumor therapy. Int J Nanomedicine (2017) 0.75
A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. Support Care Cancer (2017) 0.75
Standardisation of spirometry. Eur Respir J (2005) 48.20
Interpretative strategies for lung function tests. Eur Respir J (2005) 21.50
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
General considerations for lung function testing. Eur Respir J (2005) 7.99
Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J (2005) 7.58
Standardisation of the measurement of lung volumes. Eur Respir J (2005) 7.48
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol (1983) 4.94
Redressing the balance--the ethics of not entering an eligible patient on a randomised clinical trial. Ann Oncol (1992) 4.41
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Communicating prognosis in early breast cancer: do women understand the language used? Med J Aust (1999) 3.76
Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet (1992) 3.76
Management of malignant teratoma: does referral to a specialist unit matter? Lancet (1993) 3.73
Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br Med J (Clin Res Ed) (1986) 3.52
The dynamics of change: cancer patients' preferences for information, involvement and support. Ann Oncol (1997) 3.50
Pilus and nonpilus bacterial adhesins: assembly and function in cell recognition. Cell (1993) 3.39
Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature (1999) 3.32
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Melanoma in the gastrointestinal tract. Am J Gastroenterol (1999) 3.19
Energy balance and colon cancer--beyond physical activity. Cancer Res (1997) 3.11
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Evaluation of suicide rates in rural India using verbal autopsies, 1994-9. BMJ (2003) 2.75
Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res (1989) 2.71
Sharing decisions in cancer care. Soc Sci Med (2001) 2.70
Changing character of cervical cancer in young women. BMJ (1989) 2.66
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med (1987) 2.37
Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol (2001) 2.34
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Relationship of childhood weight status to morbidity in adults. HSMHA Health Rep (1971) 2.26
Improving immunization coverage. World Health Forum (1988) 2.20
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res (2000) 2.17
Surface differentiation antigens of human mammary epithelial cells carried on the human milk fat globule. Proc Natl Acad Sci U S A (1977) 2.16
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst (1999) 2.15
Promoting patient participation and shortening cancer consultations: a randomised trial. Br J Cancer (2001) 2.13
The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure. J Exp Med (1992) 2.13
A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centres in Ontario. CMAJ (2001) 2.11
Patient participation in the cancer consultation: evaluation of a question prompt sheet. Ann Oncol (1994) 2.09
Therapy for testicular cancer in Central and Eastern Europe. Lancet (1990) 2.08
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol (1996) 2.03
Initial therapy with combination of five antibiotics in febrile patients with leukaemia and neutropenia. Lancet (1972) 1.96
Computer-based interaction analysis of the cancer consultation. Br J Cancer (1995) 1.93
Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol (2001) 1.92
Fatty acid synthetase from lactating rat mammary gland. I. Isolation and properties. J Biol Chem (1970) 1.89
Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. J Infect Dis (1978) 1.89
Letters to patients: improving communication in cancer care. Lancet (1991) 1.83
When the diagnosis is cancer: patient communication experiences and preferences. Cancer (1996) 1.82
Who should treat cancer? Lancet (1981) 1.81
Molecular cloning of a novel human gene (D11S4896E) at chromosomal region 11p15.5. Genomics (1996) 1.80
Can health workers diagnose dementia in the community? Acta Psychiatr Scand (2007) 1.74
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med (1994) 1.73
Medical audit, cancer registration, and survival in ovarian cancer. Lancet (1991) 1.73
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol (1992) 1.73
A computerized diet history questionnaire for epidemiologic studies. J Am Diet Assoc (1994) 1.70
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer (1993) 1.64
Promoting patient participation in the cancer consultation: evaluation of a prompt sheet and coaching in question-asking. Br J Cancer (1999) 1.63
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62
Suicide in the elderly in Kaniyambadi block, Tamil Nadu, South India. Int J Geriatr Psychiatry (2005) 1.62
Endocrine therapy for desmoid tumors. Cancer (1991) 1.61
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Changes in testicular cancer in Scotland. Eur J Cancer Clin Oncol (1987) 1.58
Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res (1984) 1.58
Specifications for equipment used for infant pulmonary function testing. ERS/ATS Task Force on Standards for Infant Respiratory Function Testing. European Respiratory Society/ American Thoracic Society. Eur Respir J (2000) 1.57
Evidence for an increased risk for hypertension with centrally located body fat and the effect of race and sex on this risk. Am J Epidemiol (1984) 1.57
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol (2002) 1.55
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer (1997) 1.55
Unknown primary adenocarcinoma: incidence of overinvestigation and natural history. Br Med J (1979) 1.54
Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet (1989) 1.54
Carboplatin or cisplatin? Lancet (1988) 1.53
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) Eur J Cancer (1991) 1.52
Late spontaneous anterior dislocation of an intraocular lens (IOL) with the capsular bag. Eye (Lond) (2005) 1.52
Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol (2000) 1.50
Collagen corneal shields. Surv Ophthalmol (2002) 1.49
The changing role of surgery in metastatic non-seminomatous germ cell tumour. Br J Cancer (1992) 1.49
Solar disinfection of water for diarrhoeal prevention in southern India. Arch Dis Child (2006) 1.48
Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. Cancer Res (1988) 1.47
General information tapes inhibit recall of the cancer consultation. J Clin Oncol (1993) 1.47
p21ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21ras GTPase-activating protein. Proc Natl Acad Sci U S A (1992) 1.46
Psychological and sexual changes after the cessation of breast-feeding. Obstet Gynecol (1994) 1.46
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy (2011) 1.45
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Ann Oncol (2012) 1.44
Antiemetic therapy--where do we go from here? Ann Oncol (1993) 1.43
High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol (1983) 1.42
The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group. Ann Oncol (1996) 1.41
Diacetoxypiperidinium analogs of acetylcholine. J Med Chem (1973) 1.41
The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol (1986) 1.41
Chemotherapy of advanced malignant teratomas. Br J Cancer (1980) 1.40
Transradial cardiac catheterization in elderly patients. Catheter Cardiovasc Interv (2000) 1.39
Problems with weight control during pregnancy. Med J Aust (1989) 1.39
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. BJU Int (2003) 1.38
Treatment of advanced squamous cell carcinoma of head and neck with cisplatin and continuous 96 hour infusion of 5-fluorouracil. Aust N Z J Med (1989) 1.38
Rates and factors associated with suicide in Kaniyambadi Block, Tamil Nadu, South India, 2000-2002. Int J Soc Psychiatry (2006) 1.37